Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05701800 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
A Phase 1 study of Herpes Zoster, sponsored by ModernaTX.
- Active
- Registry status
- Phase 1
- Development phase
- 659
- Enrollment target
- 20
- Study locations
NCT05701800 is a Phase 1 study of Herpes Zoster that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 659 participants, below the 2,132-participant average among 16 other Herpes Zoster trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT05701800, a Phase 1 study of Herpes Zoster, is active but no longer recruiting, sponsored by ModernaTX.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 659 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Shingrix
- BIOLOGICAL mRNA-1468
Study Locations (20)
Florida
- Meridien Research - Lakeland
- Clinical Trials of Florida, LLC - Miami
- Floridian Clinical Research - Miami Lakes
- Florida Pulmonary Research Institute, LLC - Winter Park
Texas
- Tekton Research - Austin
- Gadolin Research - Beaumont
- LinQ Research, LLC - Houston
- DM Clinical Research - Tomball
Illinois
- Great Lakes - Chicago
- DM Clinical Research- River Forest - River Forest
California
- Velocity Clinical Research - Westlake - Los Angeles
Colorado
- Tekton Research, Inc - Longmont Center - Longmont
Georgia
- Centricity Research - Columbus
Iowa
- Meridian Clinical Research - Dakota Dunes - Sioux City
Kansas
- Johnson County Clin-Trials (JCCT) - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 659 participants |
| Start Date | 2023-01-23 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05701800
The ClinicalTrials.gov registry entry for NCT05701800 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 659 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,132-participant average among 16 other Herpes Zoster trials with a reported enrollment target (69% lower). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Herpes Zoster appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05701800 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Texas, Illinois.
Frequently Asked Questions
What is clinical trial NCT05701800 about?
NCT05701800 is a clinical study titled "A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age". The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.
What is the current status of trial NCT05701800?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 659 participants. The study started on 2023-01-23. Estimated completion is 2026-06-30.
What conditions does trial NCT05701800 study?
This clinical trial studies the following conditions: Herpes Zoster.
What interventions are being tested in trial NCT05701800?
The interventions under investigation include: Placebo (BIOLOGICAL), Shingrix (BIOLOGICAL), mRNA-1468 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05701800?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05701800 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
COMPLETED · Phase 1
-
Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
COMPLETED · Phase 1
-
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
ACTIVE NOT RECRUITING
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.